^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    BIOMARKER:

    PD-1 expression

    i
    Other names: Programmed Cell Death Protein 1, CD279, SLEB2, PD-1, Programmed cell death 1, PDCD1, Systemic Lupus Erythematosus Susceptibility 2
    Entrez ID:
    5133
    Related biomarkers:
    Expression
    Others
    2d
    Pembrolizumab in Treating Patients with Stage IB-IV Mycosis Fungoides (clinicaltrials.gov)
    P2, N=9, Active, not recruiting, Mayo Clinic | Trial completion date: Oct 2024 --> Oct 2025 | Trial primary completion date: Oct 2024 --> Oct 2025
    Trial completion date • Trial primary completion date
    |
    PD-L1 (Programmed death ligand 1) • CD8 (cluster of differentiation 8) • PD-1 (Programmed cell death 1) • CD4 (CD4 Molecule)
    |
    PD-1 expression
    |
    Keytruda (pembrolizumab)
    9d
    Effects of Anti-PD1 Adjuvant Checkpoint Blockade Immunotherapy on Atypical/Dysplastic Nevi (clinicaltrials.gov)
    P=N/A, N=30, Recruiting, John Kirkwood | Not yet recruiting --> Recruiting
    Enrollment open • Checkpoint inhibition • IO biomarker • Checkpoint block
    |
    BRAF (B-raf proto-oncogene) • CD8 (cluster of differentiation 8) • PD-1 (Programmed cell death 1) • IL6 (Interleukin 6) • IL10 (Interleukin 10) • SOX10 (SRY-Box 10)
    |
    PD-1 expression
    |
    Keytruda (pembrolizumab) • Opdivo (nivolumab)
    10d
    Targeting PLCG2 Suppresses Tumor Progression, Orchestrates the Tumor Immune Microenvironment and Potentiates Immune Checkpoint Blockade Therapy for Colorectal Cancer. (PubMed, Int J Biol Sci)
    Meanwhile, knockdown of PLCG2 could potentiate the efficacy of ICB therapy. In summary, we have identified for the first time that PLCG2 could be considered a precise biomarker and promising therapeutic target for predicting CRC prognosis, optimizing individualized treatment, reversing CRC immune escape, and overcoming resistance to ICB therapy.
    Journal • Checkpoint inhibition • PD(L)-1 Biomarker • IO biomarker • Checkpoint block
    |
    PD-L1 (Programmed death ligand 1) • CD8 (cluster of differentiation 8) • PD-1 (Programmed cell death 1) • PLCG2 (Phospholipase C Gamma 2)
    |
    PD-L1 expression • PD-1 expression
    11d
    NCI-2018-02699: Nivolumab With DA-REPOCH Chemotherapy Regimen in Treating Patients With Aggressive B-Cell Non-Hodgkin's Lymphoma (clinicaltrials.gov)
    P2, N=30, Active, not recruiting, David Bond, MD | Trial completion date: Jul 2024 --> Dec 2024 | Trial primary completion date: Jul 2024 --> Dec 2024
    Trial completion date • Trial primary completion date • Combination therapy • IO biomarker
    |
    PD-L1 (Programmed death ligand 1) • BCL2 (B-cell CLL/lymphoma 2) • PD-1 (Programmed cell death 1)
    |
    PD-1 expression
    |
    Opdivo (nivolumab) • Rituxan (rituximab) • doxorubicin hydrochloride • cyclophosphamide • etoposide IV • vincristine • prednisone • Truxima (rituximab-abbs)
    13d
    Spatial context of immune checkpoints as predictors of overall survival in patients with resectable colorectal cancer independent of standard TNM stages. (PubMed, Cancer Res Commun)
    We found that the spatial context of PD-1 and TIM-3 successfully predicted the overall survival of CRC patients independent of TNM stage. Dual targeting of PD-1 and TIM-3 in mouse tumor models inhibited tumor progression and reduced T-cell exhaustion, indicating a potential strategy for improving the clinical treatment of CRC.
    Journal • MSi-H Biomarker • PD(L)-1 Biomarker • IO biomarker
    |
    MSI (Microsatellite instability) • HAVCR2 (Hepatitis A Virus Cellular Receptor 2)
    |
    MSI-H/dMMR • PD-1 expression • HAVCR2 expression
    15d
    Unravelling the Reasons Behind Limited Response to Anti-PD Therapy in ATC: A Comprehensive Evaluation of Tumor-Infiltrating Immune Cells and Checkpoints. (PubMed, Endocr Pathol)
    TIM3, the most frequently expressed ICP on CTL, followed by CTLA4, provides alternate therapeutic targets in ATC. The co-expression of multiple immune checkpoints is of great interest for ATC since these data also open the avenue for combination therapies.
    Journal • PD(L)-1 Biomarker • IO biomarker • Immune cell
    |
    PD-L1 (Programmed death ligand 1) • CTLA4 (Cytotoxic T-Lymphocyte Associated Protein 4) • HAVCR2 (Hepatitis A Virus Cellular Receptor 2) • LGALS9 (Galectin 9)
    |
    PD-L1 expression • PD-1 expression • HAVCR2 expression
    15d
    Altered immunophenotypic expression in the peripheral bladder cancer immune landscape. (PubMed, Immunol Cell Biol)
    The peripheral blood immunophenotype in patients with BC is altered compared with cancer-free individuals. Understanding this dysregulated immune profile will contribute to the identification of diagnostic and prognostic indicators to guide effective immune-targeted, personalized treatments.
    Journal • PD(L)-1 Biomarker • IO biomarker
    |
    CD8 (cluster of differentiation 8) • PD-1 (Programmed cell death 1) • HAVCR2 (Hepatitis A Virus Cellular Receptor 2) • CD4 (CD4 Molecule)
    |
    PD-1 expression
    16d
    Effect of systemic FOLFOXIRI plus bevacizumab treatment of colorectal peritoneal metastasis on local and systemic immune cells. (PubMed, Surgery)
    Our data show that immune cell distribution after systemic chemotherapy changes in peripheral blood. Interestingly, in peritoneal fluid only the inhibitory Treg population decreased and local T cells within peritoneal metastases remain unaffected. These data indicate little to no effect of systemic chemotherapy on the local immune system, supporting the need for new therapeutic options.
    Journal • PD(L)-1 Biomarker • IO biomarker • Immune cell
    |
    PD-L1 (Programmed death ligand 1) • CD8 (cluster of differentiation 8) • PD-1 (Programmed cell death 1) • IFNG (Interferon, gamma) • IL2RA (Interleukin 2 receptor, alpha) • CD4 (CD4 Molecule) • FOXP3 (Forkhead Box P3)
    |
    PD-L1 expression • PD-1 expression
    |
    Avastin (bevacizumab) • 5-fluorouracil • oxaliplatin • irinotecan • leucovorin calcium
    16d
    The Expression of PDL-1 and PD1 in the Microenvironment of Oral Squamous Cell Carcinoma. (PubMed, Asian Pac J Cancer Prev)
    PDL-1/TILS and PDL-1/TC are independent prognostic factors in OSCC and PDL1-/TILS has an important role.
    Journal • PD(L)-1 Biomarker • IO biomarker
    |
    PD-L1 (Programmed death ligand 1) • PD-1 (Programmed cell death 1)
    |
    PD-L1 expression • PD-L1 negative • PD-1 expression
    16d
    Study on correlation between CXCL13 and prognosis and immune characteristics of ovarian cancer. (PubMed, Medicine (Baltimore))
    Moreover, high expression of CXCL13 was related to a better tumor response and more extended tumor-stable stage after PD-1 blocking therapy in IMvigor210. The study concluded that CXCL13 could be a prognostic marker and a potential immunotherapy target for OC patients, especially PD-1 checkpoint blockade.
    Journal • PD(L)-1 Biomarker • IO biomarker
    |
    CXCL13 (Chemokine (C-X-C motif) ligand 13)
    |
    PD-1 expression • CXCL13 expression
    18d
    Increased PD-1/PD-L1 Immune Checkpoint Expression Is Associated With Oral Squamous Cell Carcinoma in Never-Smokers and Never-Drinkers. (PubMed, Head Neck)
    OSCC arising in never-smokers/never-drinkers exhibit heightened PD-1/PD-L1 signaling, suggesting potential efficacy of immune checkpoint therapy in this subgroup of tumors.
    Journal • PD(L)-1 Biomarker • IO biomarker
    |
    PD-L1 (Programmed death ligand 1) • PD-1 (Programmed cell death 1) • PD-L2 (Programmed Cell Death 1 Ligand 2)
    |
    PD-L1 expression • PD-L1 negative • PD-1 expression • PD-1 elevation
    19d
    Prognostic Impact of Acute and Chronic Inflammatory Interleukin Signatures in the Tumor Microenvironment of Early Breast Cancer. (PubMed, Int J Mol Sci)
    This study highlights the complex interaction between acute and chronic inflammatory interleukins in breast cancer progression and prognosis. These findings provide insight into the prognostic relevance of interleukin expression patterns in breast cancer and may inform future therapeutic strategies targeting the immune-inflammatory axis.
    Journal • PD(L)-1 Biomarker • IO biomarker
    |
    CD20 (Membrane Spanning 4-Domains A1) • CD8 (cluster of differentiation 8) • PD-1 (Programmed cell death 1) • IFNG (Interferon, gamma) • IL10 (Interleukin 10) • IL17A (Interleukin 17A) • IGKC (Immunoglobulin Kappa Constant) • IL13 (Interleukin 13) • IL21 (Interleukin 21) • IL4 (Interleukin 4) • IL5 (Interleukin 5) • CXCL1 (Chemokine (C-X-C motif) ligand 1)
    |
    PD-1 expression • CD8 expression
    19d
    High PD-1 and CTLA-4 expression correlates with host immune suppression in patients and a mouse model infected with Echinococcus multilocularis. (PubMed, Parasit Vectors)
    E. multilocularis regulated the function of T cells via the PD-1/PD-L1- and CTLA-4-dependent pathways and subsequently evaded host immune attacks. These findings provide insights for investigating the pathogenic mechanism of AE.
    Preclinical • Journal • PD(L)-1 Biomarker • IO biomarker
    |
    PD-1 (Programmed cell death 1) • CTLA4 (Cytotoxic T-Lymphocyte Associated Protein 4)
    |
    PD-1 expression • CTLA4 expression
    19d
    New benzophenone analogs from Nigrospora sphaerica and their inhibitory activity against PD-1/PD-L1 interactions. (PubMed, Bioorg Chem)
    Moreover, compound 6 modulates the PI3K/Akt pathway, which is a key downstream effector of the PD-1/PD-L1 axis. These compounds are considered promising candidates for more in-depth exploration because they could significantly inhibit PD-1/PD-L1 interactions in tumor immunotherapy.
    Journal • PD(L)-1 Biomarker • IO biomarker
    |
    CD8 (cluster of differentiation 8) • IFNG (Interferon, gamma) • IL2 (Interleukin 2)
    |
    PD-1 expression • CD8 expression
    20d
    A novel strategy of co-expressing CXCR5 and IL-7 enhances CAR-T cell effectiveness in osteosarcoma. (PubMed, Front Immunol)
    Mechanistically, C5/IL7-CAR-T cells displayed enhanced STAT5 signaling. These findings highlight the potential of CXCR5 and IL-7 co-expression to improve CAR-T cell therapy efficacy against osteosarcoma.
    Journal • CAR T-Cell Therapy • PD(L)-1 Biomarker • IO biomarker
    |
    BCL2 (B-cell CLL/lymphoma 2) • PD-1 (Programmed cell death 1) • HAVCR2 (Hepatitis A Virus Cellular Receptor 2) • TIGIT (T Cell Immunoreceptor With Ig And ITIM Domains 2) • CXCL13 (Chemokine (C-X-C motif) ligand 13) • CXCR5 (C-X-C Motif Chemokine Receptor 5) • IL7 (Interleukin 7) • MICA (MHC Class I Polypeptide-Related Sequence A) • STAT5A (Signal Transducer And Activator Of Transcription 5A) • MICB (MHC Class I Polypeptide-Related Sequence B) • NKG2D (killer cell lectin like receptor K1)
    |
    PD-1 expression • BCL2 expression • HAVCR2 expression • CXCL13 expression • CXCR5 expression
    22d
    A Four-Gene Autophagy-Related Prognostic Model Signature and Its Association With Immune Phenotype in Lung Squamous Cell Carcinoma. (PubMed, Cancer Rep (Hoboken))
    This study provided an effective autophagy-related prognostic signature, which could also predict the immune phenotype.
    Journal • PD(L)-1 Biomarker • IO biomarker
    |
    PD-1 (Programmed cell death 1) • CTLA4 (Cytotoxic T-Lymphocyte Associated Protein 4) • CFLAR (CASP8 and FADD-like apoptosis regulator) • CTSD (Cathepsin D)
    |
    PD-1 expression • CTLA4 expression
    23d
    A splicing isoform of PD-1 promotes tumor progression as a potential immune checkpoint. (PubMed, Nat Commun)
    In vivo, T cell-specific exogenous expression of PD-1^28 promotes tumor growth in both a syngeneic mouse tumor model and humanized NOG mice inoculated with human lung cancer cells. Our study thus demonstrates that PD-1^28 functions as an immune checkpoint, and may contribute to resistance to immune checkpoint blockade therapy.
    Journal • PD(L)-1 Biomarker • IO biomarker
    |
    PD-1 (Programmed cell death 1) • TAF15 (TATA-Box Binding Protein Associated Factor 15)
    |
    PD-1 expression
    24d
    A Comprehensive Study on the Prognostic Value and Clinicopathological Significance of Different Immune Checkpoints in Patients With Colorectal Cancer: A Systematic Review and Meta-Analysis. (PubMed, Curr Ther Res Clin Exp)
    Overexpression of B7H3, B7H4, PD-1, PD-L1, PD-L2, CD70, and Galectin-3 on tumors is significantly associated with unfavorable clinicopathological characteristics and poor prognostic factors. Hence, these immune checkpoints can serve as predictive biomarkers for prognosis and the clinicopathological features of colorectal cancer because this is essential to identify patients suitable for anticancer therapy with immune checkpoint inhibitors.
    Retrospective data • Review • Journal • PD(L)-1 Biomarker • IO biomarker
    |
    PD-L1 (Programmed death ligand 1) • PD-1 (Programmed cell death 1) • CD276 (CD276 Molecule) • PD-L2 (Programmed Cell Death 1 Ligand 2) • VTCN1 (V-Set Domain Containing T Cell Activation Inhibitor 1) • CD70 (CD70 Molecule) • LGALS3 (Galectin 3)
    |
    CD276 overexpression • PD-1 expression • CD70 expression • PD-L2 expression
    24d
    The prognostic and therapeutic value of the tumor microenvironment and immune checkpoints in pancreatic neuroendocrine neoplasms. (PubMed, Sci Rep)
    The immunological landscape of Pan-NEN offers potential prognostic value and therapeutic targets. The findings suggest that immunotherapy, particularly targeting the PD-1/PD-L1 pathway, may serve as a promising strategy for the treatment of Pan-NEN, especially for Pan-NEC patients.
    Journal • PD(L)-1 Biomarker • IO biomarker
    |
    CD8 (cluster of differentiation 8) • CD163 (CD163 Molecule) • CD4 (CD4 Molecule) • CD69 (CD69 Molecule) • NCAM1 (Neural cell adhesion molecule 1) • CD68 (CD68 Molecule) • GZMB (Granzyme B) • FOXP3 (Forkhead Box P3)
    |
    PD-L1 expression • PD-L1 underexpression • PD-1 expression • CD163 expression • FOXP3 expression
    26d
    P2X7 receptor in macrophage polarization and its implications in neuroblastoma tumor behavior. (PubMed, Purinergic Signal)
    Taken together, our data underscore the regulatory function of the P2X7 receptor in orchestrating alternative macrophage polarization and in the interplay between tumor cells and TAMs. These findings help to clarify the complex interplay of purinergic signaling in cancer progression and open up avenues for future research and therapeutic interventions.
    Journal
    |
    TNFA (Tumor Necrosis Factor-Alpha) • CD73 (5'-Nucleotidase Ecto) • NT5E (5'-Nucleotidase Ecto) • ENTPD1 (Ectonucleoside Triphosphate Diphosphohydrolase 1) • MRC1 (Mannose Receptor C-Type 1) • NOS2 (Nitric Oxide Synthase 2)
    |
    PD-1 expression
    28d
    Acetylcysteine synergizes PD-1 blockers against colorectal cancer progression by promoting TCF1+PD1+CD8+ T cell differentiation. (PubMed, Cell Commun Signal)
    Our study provides a novel idea for immunotherapy for clinically progressive CRC and suggests that Glut4 may be a new immunometabolic molecular target for regulating CD8+ T cell differentiation.
    Journal • PD(L)-1 Biomarker • IO biomarker
    |
    CD8 (cluster of differentiation 8) • SLC2A4 (Solute Carrier Family 2 Member 4)
    |
    PD-1 expression • CD8 expression
    29d
    The tumor immune microenvironment of SCLC is not associated with its molecular subtypes. (PubMed, Eur J Cancer)
    SCLC TME is highly heterogeneous. Immune-hot tumors were associated with OS but not with molecular classification. PD1 expression and PD-L1 expression by immune cells may thus serve as a prognostic marker.
    Journal • PD(L)-1 Biomarker • IO biomarker
    |
    PD-L1 (Programmed death ligand 1) • CD20 (Membrane Spanning 4-Domains A1) • CD8 (cluster of differentiation 8) • PD-1 (Programmed cell death 1) • YAP1 (Yes associated protein 1) • CD4 (CD4 Molecule) • ASCL1 (Achaete-Scute Family BHLH Transcription Factor 1) • NEUROD1 (Neuronal Differentiation 1)
    |
    PD-L1 expression • PD-L1 overexpression • PD-L1 underexpression • PD-1 expression
    29d
    The Potential Role of SNRPD1 Stabilized by IGF2BP2 in the Progression of Triple-Negative Breast Cancer. (PubMed, Breast Cancer (Dove Med Press))
    IGF2BP2 and SNRPD1 were significantly highly expressed in TNBC cells. IGF2BP2 might enhance the stability and protein expression of SNRPD1 through m6A-dependent mechanisms, potentially contributing to the progression of TNBC.
    Journal
    |
    IGF2BP2 (Insulin Like Growth Factor 2 MRNA Binding Protein 2)
    |
    PD-1 expression
    1m
    Combination of Losartan and Platinum Nanoparticles with Photothermal Therapy Induces Immunogenic Cell Death Effective Against Neuroblastoma. (PubMed, Int J Nanomedicine)
    This study demonstrated that losartan-induced fibroblasts ablation increased the penetration of MPNs into tumors. Enhanced penetration allowed PTT to kill more tumor cells and synergistically activate immune cells, leading to ICD, indicating the great promise of the strategy for treating neuroblastoma in vivo.
    Journal • PD(L)-1 Biomarker • IO biomarker
    |
    CD8 (cluster of differentiation 8) • PD-1 (Programmed cell death 1) • CD4 (CD4 Molecule) • HMGB1 (High Mobility Group Box 1) • CALR (Calreticulin)
    |
    PD-1 expression
    1m
    Addition of nivolumab tailored by expansion of CAR-T cells in patients with stable/progressive large B cell lymphoma at lymphodepletion - a phase 2, prospective interventional study. (PubMed, Transplant Cell Ther)
    We conclude that the addition of nivolumab based on CAR-T cell expansion in patients with SD/PD-LBCL is safe and yields promising early response rates.
    P2 data • Journal • CAR T-Cell Therapy • PD(L)-1 Biomarker • IO biomarker
    |
    CD8 (cluster of differentiation 8) • PD-1 (Programmed cell death 1) • CD27 (CD27 Molecule)
    |
    PD-1 expression
    |
    Opdivo (nivolumab) • Yescarta (axicabtagene ciloleucel) • Kymriah (tisagenlecleucel-T)
    1m
    LncRNA MEG3 suppresses hepatocellular carcinoma by stimulating macrophage M1 polarization and modulating immune system via inhibiting CSF-1 in vivo/vitro studies. (PubMed, Int J Biol Macromol)
    MEG3 modulates the TME by affecting TAMs through CSF-1, thereby influencing the balance of Th1/Th2 cells and altering the expression of PD-1/PD-L1s. This study demonstrates that targeting MEG3 is an effective therapeutic strategy for HCC.
    Preclinical • Journal • PD(L)-1 Biomarker • IO biomarker
    |
    CSF1 (Colony stimulating factor 1) • MEG3 (Maternally Expressed 3)
    |
    PD-L1 expression • PD-1 expression
    1m
    PD-1 expression in tumor infiltrating lymphocytes as a prognostic marker in early-stage non-small cell lung cancer. (PubMed, Front Oncol)
    These findings indicate that elevated PD-1 expression on TILs can be associated with immune evasion during the early stages of malignancy evolution in the NSCLC setting and further research is required to further delineate the role of PD-1/PD-L1 pathway on tumor immune senescence. These results underline the potential role of PD-1/PD-L1 inhibitors in the treatment of early-stage NSCLC.
    Journal • Tumor-infiltrating lymphocyte • PD(L)-1 Biomarker • IO biomarker
    |
    PD-1 (Programmed cell death 1)
    |
    PD-L1 expression • PD-1 overexpression • PD-1 expression • PD-1 elevation • PD-1 positive
    1m
    Effects of Ruxolitinib on Immune Checkpoint Molecule Expression in JAK2 V617F-Positive Cells. (PubMed, Clin Lab)
    Ruxolitinib reduces the expression of p-JAK2, PD-1, and PD-L1 in JAK2 V617F-positive cells by specifically inhibiting the JAK2 signaling pathway, thereby suppressing the progression of MPNs.
    Journal • PD(L)-1 Biomarker • IO biomarker
    |
    JAK2 (Janus kinase 2) • PD-1 (Programmed cell death 1)
    |
    PD-L1 expression • PD-1 expression • JAK2 V617F • JAK2 mutation
    |
    Jakafi (ruxolitinib)
    1m
    Immunological responses to brain metastasis stereotactic radiosurgery in patient-matched longitudinal blood and tumour samples. (PubMed, Clin Transl Radiat Oncol)
    A sizeable proportion of T cell clonotypes were retained post-SRS, and four clones demonstrated significant, non-stochastic expansion. Systemic and local immunological changes in this homogenous patient cohort suggest that SRS may facilitate MHC-II-restricted T cell priming responses involving the monocyte-macrophage lineage and CD4+ T cells, which should be further explored.
    Journal • PD(L)-1 Biomarker • IO biomarker • Surgery
    |
    HER-2 (Human epidermal growth factor receptor 2) • PD-L1 (Programmed death ligand 1) • CD8 (cluster of differentiation 8) • PD-1 (Programmed cell death 1) • CD4 (CD4 Molecule)
    |
    PD-L1 expression • HER-2 amplification • PD-1 expression • HER-2 amplification + PD-L1 expression • MHC-II expression • CD4 expression
    1m
    Oracle: Efficacy and Safety of Oral Azacitidine Compared to Investigator's Choice Therapy in Patients With Relapsed or Refractory AITL (clinicaltrials.gov)
    P3, N=86, Active, not recruiting, The Lymphoma Academic Research Organisation | Trial completion date: Jun 2024 --> Dec 2024
    Trial completion date
    |
    PD-1 (Programmed cell death 1) • BCL6 (B-cell CLL/lymphoma 6) • CXCL13 (Chemokine (C-X-C motif) ligand 13) • ICOS (Inducible T Cell Costimulator) • MME (Membrane Metalloendopeptidase)
    |
    PD-1 expression
    |
    gemcitabine • bendamustine • Istodax (romidepsin) • Onureg (azacitidine oral)
    2ms
    Alternative Strategies for Delivering Immunotherapeutics Targeting the PD-1/PD-L1 Immune Checkpoint in Cancer. (PubMed, Pharmaceutics)
    We then provide a detailed review of alternative delivery approaches, including locoregional (LDD)-, oncolytic virus (OV)-, nanoparticle (NP)-, and ultrasound and microbubble (USMB)-mediated delivery that are currently under investigation for enhancing tumor-specific delivery to minimize toxic off-tumor effects. We conclude with a commentary on key challenges associated with these delivery methods and potential strategies to mitigate them.
    Review • Journal
    |
    CD8 (cluster of differentiation 8) • PD-1 (Programmed cell death 1)
    |
    PD-1 expression • CD8 expression
    2ms
    Evaluation of PD-1 and interleukin-10-receptor expression by T lymphocytes in malignant and benign pleural effusions. (PubMed, Clin Exp Med)
    The frequency of T cells expressing PD-1 and IL-10R on CD8+ T cells is significantly lower in MPE compared to BPE regardless of the underlying disease indicating a different microenvironment in PE driven by the presence of tumor cells. Our observation spotlights the possible involvement of PD-1 and IL-10R in MPE.
    Journal • Pleural effusion • PD(L)-1 Biomarker • IO biomarker
    |
    PD-L1 (Programmed death ligand 1) • CD8 (cluster of differentiation 8) • PD-1 (Programmed cell death 1) • CD4 (CD4 Molecule) • IL10 (Interleukin 10)
    |
    PD-1 expression • CD8 expression
    2ms
    Elucidating the role of 4-hydroxy-2(3H)-benzoxazolone in chronic alcoholic liver disease via transcriptomics and metabolomics. (PubMed, Front Pharmacol)
    Its mechanism of action mainly affects the glycerophospholipid metabolic pathway to promote lipid metabolism homeostasis by regulating the expression of Etnppl, Gpcpd1, and Pla2g4c. In addition, it may also inhibit the TLR4/NF-κB signaling pathway, thereby reducing the immune-inflammatory response.
    Journal • Metabolomic study
    |
    IL6 (Interleukin 6) • TNFA (Tumor Necrosis Factor-Alpha)
    |
    PD-1 expression
    2ms
    Multi-dimensional immunotyping of human NF1-associated peripheral nerve sheath tumors uncovers tumor-associated macrophages as key drivers of immune evasion in the tumor microenvironment. (PubMed, Clin Cancer Res)
    Malignant transformation of NF1-PNST is characterized by an immunosuppressive microenvironment comprising of TAM with high expression of PD-L1, which are associated with inferior outcomes. These findings suggest a clinical potential of immune modulating therapeutics that can unleash an anti-tumor immune response.
    Journal • PD(L)-1 Biomarker • IO biomarker
    |
    PD-L1 (Programmed death ligand 1) • NF1 (Neurofibromin 1) • PD-1 (Programmed cell death 1) • CD163 (CD163 Molecule)
    |
    PD-L1 overexpression • PD-1 overexpression • PD-1 expression
    2ms
    Nivolumab, BMS-936558 in Combination with Relatlimab, BMS-986016 in Patients with Metastatic Melanoma Naïve to Prior Immunotherapy in the Metastatic Setting (clinicaltrials.gov)
    P2, N=42, Completed, John Kirkwood | Active, not recruiting --> Completed | Trial completion date: Jul 2027 --> Jul 2024 | Trial primary completion date: Jul 2027 --> Jul 2024
    Trial completion • Trial completion date • Trial primary completion date • Combination therapy • IO biomarker • Metastases
    |
    PD-1 (Programmed cell death 1) • LAG3 (Lymphocyte Activating 3)
    |
    PD-1 expression • LAG3 expression
    |
    Opdivo (nivolumab) • relatlimab (BMS-986016)
    2ms
    Validation of a PD-1/CD28 chimeric switch receptor to augment CAR-T function in dogs with spontaneous B cell lymphoma. (PubMed, iScience)
    We also demonstrate that these effects depend upon active CSR signaling. This work paves the way for in vivo studies in canine BCL patients to inform human trial design.
    Journal • PD(L)-1 Biomarker • IO biomarker
    |
    PD-L1 (Programmed death ligand 1) • PD-1 (Programmed cell death 1) • CD28 (CD28 Molecule)
    |
    PD-1 expression
    2ms
    CA209-324: An Open-Label Phase II Study of Nivolumab or Nivolumab/Ipilimumab in Adult Participants With Progessive/ Recurrent Meningioma (clinicaltrials.gov)
    P2, N=40, Active, not recruiting, Dana-Farber Cancer Institute | Recruiting --> Active, not recruiting | Trial completion date: Sep 2025 --> Dec 2025 | Trial primary completion date: Mar 2025 --> Dec 2024
    Enrollment closed • Trial completion date • Trial primary completion date
    |
    PD-L1 (Programmed death ligand 1) • PD-1 (Programmed cell death 1) • IL2RA (Interleukin 2 receptor, alpha) • CD4 (CD4 Molecule) • CD69 (CD69 Molecule) • FOXP3 (Forkhead Box P3)
    |
    PD-L1 expression • PD-1 expression
    |
    Opdivo (nivolumab) • Yervoy (ipilimumab)
    2ms
    High-resolution spiral microfluidic channel integrated electrochemical device for isolation and detection of extracellular vesicles without lipoprotein contamination. (PubMed, Biosens Bioelectron)
    PD-L1 and PD-1 expression on EVs was evaluated in 30 plasma samples (10 from healthy donors, 20 from lung cancer patients) using HiMEc and compared to the results obtained from standard tissue-based PD-L1 testing, noting that HiMEc could be utilized to select further potential candidates. The obtained results are expected to contribute positively to the clinical assessment of potential immunotherapy beneficiaries.
    Journal • PD(L)-1 Biomarker • IO biomarker
    |
    PD-L1 (Programmed death ligand 1) • PD-1 (Programmed cell death 1)
    |
    PD-L1 expression • PD-1 expression
    2ms
    Investigation of the status of immune checkpoint molecules (PD-L1 and PD-1) in meningiomas by immunohistochemistry. (PubMed, Turk J Med Sci)
    With these data, it was observed that the expression of immune checkpoint molecules PD-L1 and PD-1 increased especially in high-grade meningiomas. It may be the subject of research that these molecules may be targets of immunotherapy in the treatment of meningiomas.
    Journal • PD(L)-1 Biomarker • IO biomarker
    |
    PD-L1 (Programmed death ligand 1) • PD-1 (Programmed cell death 1)
    |
    PD-L1 expression • PD-1 expression
    2ms
    Genetic polymorphism and immunological evaluation of PD-1 in Iraqi patients with acute myeloid leukemia. (PubMed, J Adv Pharm Technol Res)
    in AML patients, there is upregulation in PD-1, which indicates that PD-1 is a possible biomarker for AML. PD-1 rs36084323 G/A may have a role in AML risk.
    Journal • PD(L)-1 Biomarker • IO biomarker
    |
    PD-1 (Programmed cell death 1)
    |
    PD-1 expression • PD-1 elevation
    2ms
    Epigenetic tuning of PD-1 expression improves exhausted T cell function and viral control. (PubMed, Nat Immunol)
    This permits improved control of chronic infection without additional immunopathology. Together, these results demonstrate that tuning PD-1 via epigenetic editing can reduce CD8+ T cell dysfunction while avoiding excess immunopathology.
    Journal • PD(L)-1 Biomarker • IO biomarker
    |
    CD8 (cluster of differentiation 8) • PD-1 (Programmed cell death 1)
    |
    PD-1 overexpression • PD-1 expression • CD8 expression
    2ms
    A prospective randomized controlled clinical study on the effect of liver tripartism combined with peginterferon α-2b and nucleoside (acid) analogues on promoting the clinical cure of chronic hepatitis B (ChiCTR2400087656)
    P=N/A, N=110, Not yet recruiting, Hospital of Chengdu University of Traditional Chinese Medicine; Hospital of Chengdu University of Traditional Chinese Medicine
    New trial • IO biomarker
    |
    PD-L1 (Programmed death ligand 1) • PD-1 (Programmed cell death 1) • CXCL8 (Chemokine (C-X-C motif) ligand 8)
    |
    PD-L1 expression • PD-1 expression